Wednesday, November 13, 2019

Optimum study Ponesimod v teriflunomide

Ponesimod won decisively in this phase 2 study in RRMS. 1333 patients were randomized. Ponesimod group had lower ARR,  by 30 percent;  less combined unique active lesions (cual) by 56 percent, and less fatigue

Ofatumumab (Novartis) v. teriflunomide in 2 phase3 trials.  They had a lower ARR and time to confirmed disability. 

No comments: